

Navegando Contra el Cancer de Pulmón: Spanish Patient Navigation

A pioneering patient awareness and navigation program to empower Hispanic/LatinX lung cancer patients in Miami, Florida

Why it Matters

More than 10,000 people who identify as Hispanic or LatinX are diagnosed with lung cancer annually in the US. Miami-Dade is the number one county with the highest number of Hispanics with lung cancer. Nearly 22% of the Hispanic/LatinX population are less likely to undergo biomarker and molecular tumor testing compared to non-Hispanic whites.

Solution

Expand the LungMATCH Navigation Program to target and provide support to the Hispanic/LatinX population. LungMATCH is an on-demand navigation service for patients and caregivers that clarifies treatment options, provides biomarker testing education, and discusses options for clinical trials.

Collaborate with community-based organizations, local hospitals, and cancer centers to promote accessible and culturally sensitive support for Hispanic/LatinX lung cancer patients and caregivers. Collaborating organizations will utilize a Spanish patient navigation educational brochure to refer patients to the LungMATCH pilot Hispanic/LatinX focused help line.

Patient navigation support: The Hispanic/LatinX navigation line will provide patients with:

1. Biomarker education (what broad vs single test means)
2. Assistance with analyzing their biomarker report
3. Clinical trial options based on their biomarker report
4. Questions to ask their oncologist at their next appointment

Follow-up on patients' goals: Navigation follow-ups will address goals set by patients during the initial discussion. Interactions will ensure patients/caregivers understand the educational topics discussed and the role of biomarker testing in treatment options. Assessments will be provided to assess the impact of the patient navigation service and materials.



[learn more >](#)

Impact

Success and utilization of Navegando Contra el Cancer de Pulmón Patient navigation will be assessed by:



Patient outcomes on biomarker testing

- Assessment surveys to gauge patient understanding, interest, and involvement in biomarker testing
- Pre- and post-surveys to measure the effect of educational materials on patient knowledge, attitudes, and perception of biomarker testing following patient navigation



Incorporation of Navegando Contra el Cancer de Pulmón Phone Line

- Number of cases involving Spanish-focused Biomarker Navigation and biomarker reports analyzed
- Number of requests for lung cancer resources including biomarker testing
- Percent of patients who received biomarker testing after patient navigation services
- Percent of patients who enrolled in a clinical trial resulting from biomarker testing report
- Percent of questions that were addressed via patient navigation



Narjust Florez (Duma), MD
Associate Director, The Cancer Health Equity Program
Florida Cancer Control and Coordination, Dana-Farber Cancer Institute
Member of the Public Health Research Group

Coral Olazagasti, MD
Medical Oncologist
Sylvester Cancer Center, University of Miami

Luis Raez, MD, FACP, FCCP
Chief Scientific Officer & Medical Director
Florida Cancer Institute/University of Miami Health Care System
Co-Director NCI/FAU Florida Cancer Center of Excellence

Luis Raez, MD, FACP, FCCP
Clinical Professor of Medicine, Herbert Wertheim College of Medicine
Clinical Professor, Director
Past-President South Society of Clinical Oncology (SSASCO)

Estelamarí Rodríguez, MD
Associate Director of Community Outreach, Thomas University
Unit of Miami Sylvester Comprehensive Cancer Center



Sanofi provided a healthcare contribution to support this initiative in addressing specific health disparity challenges. Sanofi does not direct any program content or actions.